نتایج جستجو برای: tp53

تعداد نتایج: 8206  

2018
Venkatesh Kancherla Samir Abdullazade Matthias S. Matter Manuela Lanzafame Luca Quagliata Guglielmo Roma Yujin Hoshida Luigi M. Terracciano Charlotte K. Y. Ng Salvatore Piscuoglio

The TP53 gene is the most commonly mutated gene in human cancers and mutations in TP53 have been shown to have either gain-of-function or loss-of-function effects. Using the data generated by The Cancer Genome Atlas, we sought to define the spectrum of TP53 mutations in hepatocellular carcinomas (HCCs) and their association with clinicopathologic features, and to determine the oncogenic and mut...

Journal: :Cancer research 2009
Yedael Y Waldman Tamir Tuller Roded Sharan Eytan Ruppin

The tumor suppressor gene TP53 is known to be a key regulator in cancer, and more than half of human cancers exhibit mutations in this gene. Recent evidence shows that point mutations in TP53 not only disrupt its function but also possess gain-of-function and dominant-negative effects on wild-type copies, thus making the mutated gene an oncogene. Hence, this brings about the possibility that TP...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2014
Laxmi Silwal-Pandit Hans Kristian Moen Vollan Suet-Feung Chin Oscar M Rueda Steven McKinney Tomo Osako David A Quigley Vessela N Kristensen Samuel Aparicio Anne-Lise Børresen-Dale Carlos Caldas Anita Langerød

PURPOSE In breast cancer, the TP53 gene is frequently mutated and the mutations have been associated with poor prognosis. The prognostic impact of the different types of TP53 mutations across the different molecular subtypes is still poorly understood. Here, we characterize the spectrum and prognostic significance of TP53 mutations with respect to the PAM50 subtypes and integrative clusters (IC...

2018
Haruna Furukawa Tomoki Makino Makoto Yamasaki Koji Tanaka Yasuhiro Miyazaki Tsuyoshi Takahashi Yukinori Kurokawa Kiyokazu Nakajima Shuji Takiguchi Masaki Mori Yuichiro Doki

TP53 is associated with the resistance of cytotoxic treatment and patient prognosis, and the mutation rate of TP53 in esophageal squamous cell carcinoma (ESCC) is extraordinarily high, at over 90%. PRIMA-1 (p53 re-activation and induction of massive apoptosis) has recently been reported to restore the function of mutant TP53; however, its antitumor effect and mechanism in ESCC remain unclear. A...

Journal: :Pathobiology : journal of immunopathology, molecular and cellular biology 2012
Eduardo Henrique Cunha Neves Filho Denise Ellen Francelino Cordeiro Ana Patrícia Freitas Vieira Silvia Helena Barem Rabenhorst

Although TP53 alterations have been studied in human tumors, data considering the role of two common TP53 polymorphisms (Pro72Arg in codon 72 and Ins16bp in intron 3) and their associations with TP53 mutations in gastric cancer are very limited. Thus, we analyzed these parameters taking into consideration the clinicopathological data. DNA from 106 gastric tumor samples was available for TP53 Pr...

2015
Sebastian Ribi Daniel Baumhoer Kristy Lee Edison Audrey S.M. Teo Babita Madan Kang Zhang Wendy K. Kohlmann Fei Yao Wah Heng Lee Qiangze Hoi Shaojiang Cai Xing Yi Woo Patrick Tan Gernot Jundt Jan Smida Michaela Nathrath Wing-Kin Sung Joshua D. Schiffman David M. Virshup Axel M. Hillmer

Somatic mutations of TP53 are among the most common in cancer and germline mutations of TP53 (usually missense) can cause Li-Fraumeni syndrome (LFS). Recently, recurrent genomic rearrangements in intron 1 of TP53 have been described in osteosarcoma (OS), a highly malignant neoplasm of bone belonging to the spectrum of LFS tumors. Using whole-genome sequencing of OS, we found features of TP53 in...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2015
Svasti Haricharan Powel Brown

Breast cancer is a leading cause of cancer-related death, and it is important to understand pathways that drive the disease to devise effective therapeutic strategies. Our results show that Toll-like receptor 4 (TLR4) drives breast cancer cell growth differentially based on the presence of TP53, a tumor suppressor. TP53 is mutationally inactivated in most types of cancer and is mutated in 30-50...

2014
Agnieszka Zając Beata Smolarz Grzegorz Stachowiak Jacek R. Wilczyński

The aim of the study was to determine an association of TP53 codon 72 (Arg72Pro, G>C transversion, rs1042522) and MDM2 SNP309 (T>G change, rs2279744) polymorphisms in endometrial cancer (EC) of postmenopausal women, regarding grading and staging of EC. In the study, endometrial samples from 202 postmenopausal female patients (the study group, n = 152, was women with EC; the control group, n = 5...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2005
Koert P de Jong Annette S H Gouw Paul M J G Peeters Marian Bulthuis Lorian Menkema Robert J Porte Maarten J H Slooff Harry van Goor Anke van den Berg

PURPOSE To correlate TP53 mutations with angiogenic status of the tumor and prognosis after liver surgery in patients with colorectal liver metastases and to correlate immunohistochemical staining of p53 protein with TP53 gene mutations. EXPERIMENTAL DESIGN Tumors of 44 patients with surgically treated colorectal liver metastases were analyzed for (a) TP53 mutations using denaturing gradient ...

2014
Heather R. Shive Robert R. West Lisa J. Embree Champa D. Golden Dennis D. Hickstein

Germline mutations in the tumor suppressor genes BRCA2 and TP53 significantly influence human cancer risk, and cancers from humans who inherit one mutant allele for BRCA2 or TP53 often display loss of the wildtype allele. In addition, BRCA2-associated cancers often exhibit mutations in TP53. To determine the relationship between germline heterozygous mutation (haploinsufficiency) and somatic lo...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید